Teaching the Immune System to Let Medicines Do Their Job

Carsten Brunn, president and CEO of Selecta Biosciences, discusses the problem of immunogenicity to biologics, the company’s ImmTOR platform, and how its leveraging that platform with a growing pipeline of biologics and gene therapies.